[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Perphenazine enanthate.]
[N05AL01, sulpiride, Perphenazine enanthate may increase the antipsychotic activities of Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Sulthiame is combined with Perphenazine enanthate.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Perphenazine enanthate.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Perphenazine enanthate.]
[L01CB02, teniposide, Teniposide may increase the neurotoxic activities of Perphenazine enanthate.]
[N07XX06, tetrabenazine, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Tetracaine is combined with Perphenazine enanthate.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Lurasidone is combined with Perphenazine enanthate.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine enanthate.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Perphenazine enanthate.]
[L04AX02, thalidomide, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Perphenazine enanthate.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Perphenazine enanthate.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Perphenazine enanthate.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Perphenazine enanthate.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Perphenazine enanthate.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Perphenazine enanthate.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Tiapride is combined with Perphenazine enanthate.]
[N02AX01, tilidine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Tilidine.]
[S01ED01, timolol, The serum concentration of Timolol can be increased when it is combined with Perphenazine enanthate.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Perphenazine enanthate.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Perphenazine enanthate.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Tolperisone is combined with Perphenazine enanthate.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Perphenazine enanthate is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Perphenazine enanthate.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Trazodone.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Perphenazine enanthate.]
[A03AB12, mepenzolate, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perphenazine enanthate.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Trifluperidol is combined with Perphenazine enanthate.]
[N05AA05, triflupromazine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Perphenazine enanthate.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Perphenazine enanthate.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Perphenazine enanthate.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Perphenazine enanthate.]
[A03BB01, butylscopolamine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Vilazodone is combined with Perphenazine enanthate.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Perphenazine enanthate.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Perphenazine enanthate.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Ezogabine is combined with Perphenazine enanthate.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Viloxazine is combined with Perphenazine enanthate.]
[L01CA02, vincristine, Vincristine may increase the neurotoxic activities of Perphenazine enanthate.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Perphenazine enanthate.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Perphenazine enanthate.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Ziprasidone.]
[G04BD07, tolterodine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, The serum concentration of Atenolol can be increased when it is combined with Perphenazine enanthate.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Atracurium is combined with Perphenazine enanthate.]
[S01FA01, atropine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Perphenazine enanthate.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Perphenazine enanthate.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Perphenazine enanthate.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine enanthate.]
[N04BD02, rasagiline, The risk or severity of extrapyramidal symptoms can be increased when Rasagiline is combined with Perphenazine enanthate.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Mosapride is combined with Perphenazine enanthate.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Perphenazine enanthate.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Perphenazine enanthate.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Perphenazine enanthate.]
[R06AC06, thonzylamine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Diethyl ether is combined with Perphenazine enanthate.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Perphenazine enanthate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Benperidol is combined with Perphenazine enanthate.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Perphenazine enanthate.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Perphenazine enanthate.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Perphenazine enanthate.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Perphenazine enanthate.]
[N04AC01, benztropine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Perphenazine enanthate.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Perphenazine enanthate.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Levomilnacipran.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Vortioxetine is combined with Perphenazine enanthate.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Perphenazine enanthate.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Perphenazine enanthate.]
[C07AB04, acebutolol, The serum concentration of Acebutolol can be increased when it is combined with Perphenazine enanthate.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Tasimelteon is combined with Perphenazine enanthate.]
[S01ED02, betaxolol, The serum concentration of Betaxolol can be increased when it is combined with Perphenazine enanthate.]
[A03BA03, hyoscyamine, Perphenazine enanthate may increase the anticholinergic activities of Hyoscyamine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Alfaxalone is combined with Perphenazine enanthate.]
[D11AA01, glycopyrronium, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Perphenazine enanthate.]
[A06AH03, naloxegol, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Naloxegol.]
[N04AA02, biperiden, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[N06AX11, mirtazapine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[A03AA09, difemerine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[A07DA06, eluxadoline, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Perphenazine enanthate.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Flibanserin is combined with Perphenazine enanthate.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Cariprazine is combined with Perphenazine enanthate.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Perphenazine enanthate.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Perphenazine enanthate.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Perphenazine enanthate.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Perphenazine enanthate.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Perphenazine enanthate.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Brivaracetam is combined with Perphenazine enanthate.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Perphenazine enanthate.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Perphenazine enanthate.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Perphenazine enanthate.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perphenazine enanthate.]
[N06AA19, amineptin, The serum concentration of Amineptine can be increased when it is combined with Perphenazine enanthate.]
[N05AX17, pimavanserin, Pimavanserin may increase the neurotoxic activities of Perphenazine enanthate.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Perphenazine enanthate.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Perphenazine enanthate.]
[C07AA19, bupranolol, The serum concentration of Bupranolol can be increased when it is combined with Perphenazine enanthate.]
[N07BC01, buprenorphine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Perphenazine enanthate.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Artemether is combined with Perphenazine enanthate.]
[P01BE03, artesunate, The risk or severity of QTc prolongation can be increased when Artesunate is combined with Perphenazine enanthate.]
[N02AF01, butorphanol, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Butorphanol.]
[S01GX07, azelastine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[N07XX16, deutetrabenazine, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Perphenazine enanthate can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Beclamide is combined with Perphenazine enanthate.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Perphenazine enanthate.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XX08, linezolid, The risk or severity of extrapyramidal symptoms can be increased when Linezolid is combined with Perphenazine enanthate.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Perphenazine enanthate.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Perphenazine enanthate.]
[N04BD03, safinamide, The risk or severity of extrapyramidal symptoms can be increased when Safinamide is combined with Perphenazine enanthate.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Perphenazine enanthate.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Perphenazine enanthate.]
[C07AA17, bopindolol, The serum concentration of Bopindolol can be increased when it is combined with Perphenazine enanthate.]
[N04AA11, bornaprine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Bromperidol is combined with Perphenazine enanthate.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Brotizolam is combined with Perphenazine enanthate.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Perphenazine enanthate.]
[N06AA15, butriptyline, The serum concentration of Butriptyline can be increased when it is combined with Perphenazine enanthate.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Vinylbital is combined with Perphenazine enanthate.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Perphenazine enanthate.]
[A03AA03, camylofine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Perphenazine enanthate.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Perphenazine enanthate.]
[C07AG02, carvedilol, The serum concentration of Carvedilol can be increased when it is combined with Perphenazine enanthate.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Perphenazine enanthate.]
[C07AB08, celiprolol, The serum concentration of Celiprolol can be increased when it is combined with Perphenazine enanthate.]
[P01BA07, tafenoquine, The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Perphenazine enanthate.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Stiripentol is combined with Perphenazine enanthate.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Perphenazine enanthate.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Carbromal is combined with Perphenazine enanthate.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Perphenazine enanthate.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Perphenazine enanthate.]
[R06AA06, chlorphenoxamine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Perphenazine enanthate.]
[R03BB08, revefenacin, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Cinitapride is combined with Perphenazine enanthate.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Esketamine.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Brexanolone is combined with Perphenazine enanthate.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Perphenazine enanthate.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Perphenazine enanthate.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Cyamemazine is combined with Perphenazine enanthate.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Perphenazine enanthate.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Perphenazine enanthate.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Perphenazine enanthate.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Perphenazine enanthate.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perphenazine enanthate.]
[N02AX03, dezocine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Lemborexant is combined with Perphenazine enanthate.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Perphenazine enanthate.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Perphenazine enanthate.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Perphenazine enanthate.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Perphenazine enanthate.]
[N02AA08, dihydrocodeine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Perphenazine enanthate.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Perphenazine enanthate.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Perphenazine enanthate.]
[A03AA08, dihexyverine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[P01BE01, artemisinin, The risk or severity of QTc prolongation can be increased when Artemisinin is combined with Perphenazine enanthate.]
[G04BD09, trospium, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Clomethiazole is combined with Perphenazine enanthate.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Perphenazine enanthate.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Perphenazine enanthate.]
[P01BB01, proguanil, The risk or severity of QTc prolongation can be increased when Proguanil is combined with Perphenazine enanthate.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Perphenazine enanthate is combined with Remimazolam.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Perphenazine enanthate is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Perphenazine enanthate.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Perphenazine enanthate.]
[N05AA01, chlorpromazine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Perphenazine enanthate.]
[N05AF03, chlorprothixene, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Perphenazine enanthate.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Etifoxine is combined with Perphenazine enanthate.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Vinpocetine is combined with Perphenazine enanthate.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Perphenazine enanthate.]
[L01FX21, naxitamab, Perphenazine enanthate may increase the neurotoxic activities of Naxitamab.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Febarbamate is combined with Perphenazine enanthate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Perphenazine enanthate.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Perphenazine enanthate.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Perphenazine enanthate.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Perphenazine enanthate.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Perphenazine enanthate.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Citalopram.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Perphenazine enanthate.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Perphenazine enanthate.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Perphenazine enanthate.]
[J01FF01, clindamycin, Clindamycin may increase the neurotoxic activities of Perphenazine enanthate.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when St. John's Wort is combined with Perphenazine enanthate.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Perphenazine enanthate.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Perphenazine enanthate.]
[N06AA04, clomipramine, The serum concentration of desmethylclomipramine, an active metabolite of Clomipramine, can be increased when used in combination with Perphenazine enanthate.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Perphenazine enanthate.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Perphenazine enanthate.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Clothiapine is combined with Perphenazine enanthate.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Perphenazine enanthate.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Perphenazine enanthate.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Perphenazine enanthate.]
[N05AH02, clozapine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Perphenazine enanthate.]
[S02DA02, cocaine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, The risk or severity of extrapyramidal symptoms and CNS depression can be increased when Metyrosine is combined with Perphenazine enanthate.]
[R05DA04, codeine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Codeine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Perphenazine enanthate.]
[A03AB10, hexocyclium, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Perphenazine enanthate.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Tropisetron is combined with Perphenazine enanthate.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Ifenprodil is combined with Perphenazine enanthate.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Perphenazine enanthate.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Perphenazine enanthate.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Perphenazine enanthate.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Perphenazine enanthate.]
[N03AX09, lamotrigine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Perphenazine enanthate can be increased when used in combination with Lofexidine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Lormetazepam is combined with Perphenazine enanthate.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03AA04, mebeverine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Medifoxamine is combined with Perphenazine enanthate.]
[C07AA14, mepindolol, The serum concentration of Mepindolol can be increased when it is combined with Perphenazine enanthate.]
[R06AD07, mequitazine, Perphenazine enanthate may increase the arrhythmogenic activities of Mequitazine.]
[N04AA03, methixene, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, Perphenazine enanthate may decrease the stimulatory activities of Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Perphenazine enanthate.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Cyclobarbital is combined with Perphenazine enanthate.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Melperone is combined with Perphenazine enanthate.]
[L01AA01, cyclophosphamide, Cyclophosphamide may increase the neurotoxic activities of Perphenazine enanthate.]
[N06AX07, minaprine, The risk or severity of extrapyramidal symptoms can be increased when Minaprine is combined with Perphenazine enanthate.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Perphenazine enanthate.]
[S01XA18, cyclosporine, Cyclosporine may increase the neurotoxic activities of Perphenazine enanthate.]
[N06AG02, moclobemide, The risk or severity of extrapyramidal symptoms can be increased when Moclobemide is combined with Perphenazine enanthate.]
[R06AX02, cyproheptadine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Perphenazine enanthate.]
[J04BA02, dapsone, The risk or severity of QTc prolongation can be increased when Dapsone is combined with Perphenazine enanthate.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Deanol is combined with Perphenazine enanthate.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Perphenazine enanthate.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Nordazepam is combined with Perphenazine enanthate.]
[C07AB12, nebivolol, The serum concentration of Nebivolol can be increased when it is combined with Perphenazine enanthate.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Niaprazine is combined with Perphenazine enanthate.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Perphenazine enanthate.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Perphenazine enanthate.]
[R05DA06, normethadone, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Escitalopram.]
[G04BD08, solifenacin, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, The serum concentration of Desipramine can be increased when it is combined with Perphenazine enanthate.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Perphenazine enanthate.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Oxiracetam is combined with Perphenazine enanthate.]
[N04AA08, dexetimide, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, Perphenazine enanthate may decrease the stimulatory activities of Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Perphenazine enanthate.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Perphenazine enanthate.]
[N02AC01, dextromoramide, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Dextromoramide.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Perphenazine enanthate.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Diamorphine.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Perphenazine enanthate.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Perphenazine enanthate.]
[R03BB01, ipratropium bromide, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N07XX04, sodium oxybate, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Perphenazine enanthate.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Perphenazine enanthate.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Perphenazine enanthate.]
[N06AA08, dibenzepin, The serum concentration of Dibenzepin can be increased when it is combined with Perphenazine enanthate.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Perphenazine enanthate.]
[A03AA07, dicyclomine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may increase the neurotoxic activities of Perphenazine enanthate.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Pipamperone is combined with Perphenazine enanthate.]
[A03AB14, pipenzolate, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[A08AA03, diethylpropion, Perphenazine enanthate may decrease the stimulatory activities of Diethylpropion.]
[A03AB11, poldine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Perphenazine enanthate.]
[N02AA03, hydromorphone, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Hydromorphone.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Perphenazine enanthate.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Pramocaine is combined with Perphenazine enanthate.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Perphenazine enanthate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Pridinol is combined with Perphenazine enanthate.]
[R06AB03, dimethindene, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Perphenazine enanthate.]
[R06AA02, diphenhydramine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Perphenazine enanthate.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The serum concentration of Quinupramine can be increased when it is combined with Perphenazine enanthate.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Perphenazine enanthate.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Perphenazine enanthate.]
[C01BA03, disopyramide, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Perphenazine enanthate.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Perphenazine enanthate.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Levocetirizine is combined with Perphenazine enanthate.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Perphenazine enanthate.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Perphenazine enanthate.]
[N06AA16, dothiepin, The serum concentration of Dosulepin can be increased when it is combined with Perphenazine enanthate.]
[N06AA12, doxepin, The serum concentration of Doxepin can be increased when it is combined with Perphenazine enanthate.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine enanthate.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Perphenazine enanthate.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine enanthate.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Sibutramine.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Sultopride is combined with Perphenazine enanthate.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Perphenazine enanthate.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Perphenazine enanthate.]
[C07AA16, tertatolol, The serum concentration of Tertatolol can be increased when it is combined with Perphenazine enanthate.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Tetrazepam is combined with Perphenazine enanthate.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Perphenazine enanthate.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Thiopropazate is combined with Perphenazine enanthate.]
[G04BD01, emepronium, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The serum concentration of Tianeptine can be increased when it is combined with Perphenazine enanthate.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Tofisopam is combined with Perphenazine enanthate.]
[N06AG03, toloxatone, The risk or severity of extrapyramidal symptoms can be increased when Toloxatone is combined with Perphenazine enanthate.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Perphenazine enanthate.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Loprazolam is combined with Perphenazine enanthate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Triclofos is combined with Perphenazine enanthate.]
[A03AB08, tridihexethyl, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Perphenazine enanthate.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Perphenazine enanthate.]
[N04AA12, tropatepine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Perphenazine enanthate.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Urapidil is combined with Perphenazine enanthate.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Veralipride is combined with Perphenazine enanthate.]
[L01CA04, vinorelbine, Vinorelbine may increase the neurotoxic activities of Perphenazine enanthate.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Perphenazine enanthate.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Perphenazine enanthate.]
[N05CF02, zolpidem, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Perphenazine enanthate.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Perphenazine enanthate.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Zotepine is combined with Perphenazine enanthate.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Perphenazine enanthate.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Perphenazine enanthate.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Perphenazine enanthate.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perphenazine enanthate.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Ergotamine is combined with Perphenazine enanthate.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Perphenazine enanthate.]
[C01CA15, gepefrine, Perphenazine enanthate may decrease the stimulatory activities of Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perphenazine enanthate.]
[N04AA05, profenamine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Perphenazine enanthate.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Perphenazine enanthate.]
[S01XA06, ethylmorphine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Ethylmorphine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Perphenazine enanthate.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Sertindole is combined with Perphenazine enanthate.]
[R06AX12, terfenadine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Perphenazine enanthate.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Fluvoxamine.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Perphenazine enanthate.]
[N02AB03, fentanyl, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Fentanyl.]
[G04BD02, flavoxate, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Flunarizine is combined with Perphenazine enanthate.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Perphenazine enanthate.]
[N06AA14, melitracen, The serum concentration of Melitracen can be increased when it is combined with Perphenazine enanthate.]
[V03AZ01, ethanol, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Perphenazine enanthate.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Perphenazine enanthate.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Perphenazine enanthate.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Alcuronium is combined with Perphenazine enanthate.]
[G01AX06, furazolidone, The risk or severity of extrapyramidal symptoms can be increased when Furazolidone is combined with Perphenazine enanthate.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Perphenazine enanthate is combined with Eszopiclone.]
[N05AL05, amisulpride, Perphenazine enanthate may increase the antipsychotic activities of Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gallamine is combined with Perphenazine enanthate.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Barbexaclone is combined with Perphenazine enanthate.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Bifemelane is combined with Perphenazine enanthate.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Perphenazine enanthate.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Perphenazine enanthate.]
[N01AH02, alfentanil, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Alfentanil.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Perphenazine enanthate.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Perphenazine enanthate.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Perphenazine enanthate.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perphenazine enanthate.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Perphenazine enanthate.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Perphenazine enanthate.]
[C07AB09, esmolol, The serum concentration of Esmolol can be increased when it is combined with Perphenazine enanthate.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Perphenazine enanthate.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Perphenazine enanthate.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Perphenazine enanthate.]
[N05AH04, quetiapine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Perphenazine enanthate.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Iprazochrome is combined with Perphenazine enanthate.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Allobarbital is combined with Perphenazine enanthate.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Perphenazine enanthate.]
[R05DA03, hydrocodone, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[G04BD06, propiverine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Perphenazine enanthate.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Prothipendyl is combined with Perphenazine enanthate.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine enanthate.]
[B05CB02, sodium citrate, Sodium citrate may increase the neurotoxic activities of Perphenazine enanthate.]
[N01AH03, sufentanil, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Sufentanil.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Perphenazine enanthate.]
[L01CD01, paclitaxel, Paclitaxel may increase the neurotoxic activities of Perphenazine enanthate.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Perphenazine enanthate.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Milnacipran.]
[A03AA30, piperidolate, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Articaine is combined with Perphenazine enanthate.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Perphenazine enanthate.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Perphenazine enanthate.]
[R06AE01, buclizine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C07AA01, alprenolol, The serum concentration of Alprenolol can be increased when it is combined with Perphenazine enanthate.]
[J05AF04, stavudine, Stavudine may increase the neurotoxic activities of Perphenazine enanthate.]
[N06AA13, iprindole, The serum concentration of Iprindole can be increased when it is combined with Perphenazine enanthate.]
[N06AF05, iproniazid, The risk or severity of extrapyramidal symptoms can be increased when Iproniazid is combined with Perphenazine enanthate.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Chlorproethazine is combined with Perphenazine enanthate.]
[N06AF01, isocarboxazid, The risk or severity of extrapyramidal symptoms can be increased when Isocarboxazid is combined with Perphenazine enanthate.]
[P01AX06, atovaquone, The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Perphenazine enanthate.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Perphenazine enanthate.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Perphenazine enanthate.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Perphenazine enanthate.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Perphenazine enanthate.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Ketanserin is combined with Perphenazine enanthate.]
[N05AH03, olanzapine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[N04BC09, rotigotine, Perphenazine enanthate may increase the sedative activities of Rotigotine.]
[C07AG01, labetalol, The serum concentration of Labetalol can be increased when it is combined with Perphenazine enanthate.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Perphenazine enanthate.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Levodopa is combined with Perphenazine enanthate.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Perphenazine enanthate.]
[J01FF02, lincomycin, Lincomycin may increase the neurotoxic activities of Perphenazine enanthate.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Perphenazine enanthate.]
[N06AA07, lofepramine, The serum concentration of Lofepramine can be increased when it is combined with Perphenazine enanthate.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Perphenazine enanthate.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Perphenazine enanthate.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Perphenazine enanthate can be increased when used in combination with Magnesium sulfate.]
[N06AA21, maprotiline, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Perphenazine enanthate.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Perphenazine enanthate.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Medazepam is combined with Perphenazine enanthate.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Perphenazine enanthate.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Perphenazine enanthate.]
[N02AB02, meperidine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Meperidine.]
[C01CA11, mephentermine, Perphenazine enanthate may decrease the stimulatory activities of Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Perphenazine enanthate.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Perphenazine enanthate.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Perphenazine enanthate.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Perphenazine enanthate.]
[N02AX05, meptazinol, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Perphenazine enanthate.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Paliperidone is combined with Perphenazine enanthate.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Perphenazine enanthate.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Perphenazine enanthate.]
[N06BA03, methamphetamine, Perphenazine enanthate may decrease the stimulatory activities of Metamfetamine.]
[A03AB07, methantheline, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Perphenazine enanthate.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Perphenazine enanthate.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Perphenazine enanthate.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Metergoline is combined with Perphenazine enanthate.]
[H03BB02, methimazole, The therapeutic efficacy of Methimazole can be decreased when used in combination with Perphenazine enanthate.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Perphenazine enanthate.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Perphenazine enanthate.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Perphenazine enanthate is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Perphenazine enanthate.]
[V04CG05, methylene blue, The risk or severity of extrapyramidal symptoms can be increased when Methylene blue is combined with Perphenazine enanthate.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Perphenazine enanthate.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Perphenazine enanthate.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Perphenazine enanthate.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Perphenazine enanthate.]
[C07AB02, metoprolol, The serum concentration of Metoprolol can be increased when it is combined with Perphenazine enanthate.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Mianserin is combined with Perphenazine enanthate.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Perphenazine enanthate.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Perphenazine enanthate.]
[N06BA12, lisdexamfetamine, Perphenazine enanthate may decrease the stimulatory activities of Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Perphenazine enanthate.]
[N06AA09, amitriptyline, The serum concentration of Amitriptyline can be increased when it is combined with Perphenazine enanthate.]
[N02AA01, morphine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Morphine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Perphenazine enanthate.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Perphenazine enanthate.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Perphenazine enanthate.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Perphenazine enanthate.]
[N06AA17, amoxapine, The serum concentration of Amoxapine can be increased when it is combined with Perphenazine enanthate.]
[N03AB05, fosphenytoin, The serum concentration of Fosphenytoin can be increased when it is combined with Perphenazine enanthate.]
[C07AA12, nadolol, The serum concentration of Nadolol can be increased when it is combined with Perphenazine enanthate.]
[N04BC04, ropinirole, Perphenazine enanthate may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Naftidrofuryl is combined with Perphenazine enanthate.]
[N02AF02, nalbuphine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Nalbuphine.]
[N07BB04, naltrexone, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Naltrexone.]
[N06BA01, amphetamine, Perphenazine enanthate may decrease the stimulatory activities of Amphetamine.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Perphenazine enanthate.]
[S03AA01, neomycin, Neomycin may increase the neurotoxic activities of Perphenazine enanthate.]
[N01AH06, remifentanil, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Remifentanil.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Iloperidone is combined with Perphenazine enanthate.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Perphenazine enanthate is combined with Desvenlafaxine.]
[N06AF02, nialamide, The risk or severity of extrapyramidal symptoms can be increased when Nialamide is combined with Perphenazine enanthate.]
[C08CA04, nicardipine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Perphenazine enanthate.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Perphenazine enanthate.]
[N04BC05, pramipexole, Perphenazine enanthate may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Perphenazine enanthate.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Perphenazine enanthate.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Perphenazine enanthate.]
[N06AA05, opipramol, The serum concentration of Opipramol can be increased when it is combined with Perphenazine enanthate.]
[N02AA02, opium, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Opium.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Perphenazine enanthate.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Perphenazine enanthate.]
[C07AA02, oxprenolol, The serum concentration of Oxprenolol can be increased when it is combined with Perphenazine enanthate.]
[N02AA05, oxycodone, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Oxycodone.]
[N02AA11, oxymorphone, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Oxypertine is combined with Perphenazine enanthate.]
[A03AB03, oxyphenonium, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Asenapine is combined with Perphenazine enanthate.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine enanthate.]
[M03AC01, pancuronium, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[N05CC05, paraldehyde, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of extrapyramidal symptoms can be increased when Pargyline is combined with Perphenazine enanthate.]
[G04BD11, fesoterodine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The serum concentration of Penbutolol can be increased when it is combined with Perphenazine enanthate.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Penfluridol is combined with Perphenazine enanthate.]
[N02AD01, pentazocine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Perphenazine enanthate.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Perazine is combined with Perphenazine enanthate.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Perphenazine enanthate.]
[N02AD02, phenazocine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of extrapyramidal symptoms can be increased when Phenelzine is combined with Perphenazine enanthate.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Phenobarbital is combined with Perphenazine enanthate.]
[N01AH04, phenoperidine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Phenoperidine.]
[A08AA01, phentermine, Perphenazine enanthate may decrease the stimulatory activities of Phentermine.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be increased when it is combined with Perphenazine enanthate.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Pimozide is combined with Perphenazine enanthate.]
[C07AA03, pindolol, The serum concentration of Pindolol can be increased when it is combined with Perphenazine enanthate.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Perphenazine enanthate.]
[A02BX03, pirenzepine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Piritramide.]
[N02CX01, pizotyline, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Proxibarbal is combined with Perphenazine enanthate.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Perphenazine enanthate.]
[S03AA03, polymyxin B, Perphenazine enanthate may increase the neurotoxic activities of Polymyxin B.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Perphenazine enanthate.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Perphenazine enanthate.]
[C07AB01, practolol, The serum concentration of Practolol can be increased when it is combined with Perphenazine enanthate.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Perphenazine enanthate.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Perphenazine enanthate.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Perphenazine enanthate.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Primidone is combined with Perphenazine enanthate.]
[S01HA05, procaine, The risk or severity of extrapyramidal symptoms can be increased when Procaine is combined with Perphenazine enanthate.]
[L01XB01, procarbazine, The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Perphenazine enanthate.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perphenazine enanthate.]
[N04AA04, procyclidine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The serum concentration of Propafenone can be increased when it is combined with Perphenazine enanthate.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Propanidid is combined with Perphenazine enanthate.]
[A03AB05, propantheline, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Periciazine is combined with Perphenazine enanthate.]
[N05CM06, propiomazine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Perphenazine enanthate.]
[N02AC04, propoxyphene, The risk or severity of hypotension and CNS depression can be increased when Perphenazine enanthate is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Perphenazine enanthate.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Perphenazine enanthate.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Perphenazine enanthate.]
[N06AA11, protriptyline, The serum concentration of Protriptyline can be increased when it is combined with Perphenazine enanthate.]
[R01BA02, pseudoephedrine, Perphenazine enanthate may decrease the stimulatory activities of Pseudoephedrine.]
[N05AX12, aripiprazole, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Perphenazine enanthate.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Vinbarbital is combined with Perphenazine enanthate.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Captodiame is combined with Perphenazine enanthate.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Styramate is combined with Perphenazine enanthate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Pyrantel is combined with Perphenazine enanthate.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Mepyramine is combined with Perphenazine enanthate.]
[P01BD01, pyrimethamine, The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Perphenazine enanthate.]
[P01AX05, quinacrine, The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Perphenazine enanthate.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Quinidine is combined with Perphenazine enanthate.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Perphenazine enanthate.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Perphenazine enanthate.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Perphenazine enanthate.]
[S01FA02, scopolamine, Perphenazine enanthate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Perphenazine enanthate.]
[N04BD01, selegiline, The risk or severity of extrapyramidal symptoms can be increased when Selegiline is combined with Perphenazine enanthate.]
[C07AA07, sotalol, The serum concentration of Sotalol can be increased when it is combined with Perphenazine enanthate.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Perphenazine.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Perphenazine.]
[N05AL01, sulpiride, Perphenazine may increase the antipsychotic activities of Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Perphenazine is combined with Sulthiame.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Perphenazine.]
[N06DA01, tacrine, The metabolism of Perphenazine can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Perphenazine.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Perphenazine.]
[L01CB02, teniposide, Teniposide may increase the neurotoxic activities of Perphenazine.]
[N07XX06, tetrabenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.]
[N04BC07, apomorphine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Perphenazine.]
[L04AX02, thalidomide, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Perphenazine.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Perphenazine.]
[P02CA02, thiabendazole, The metabolism of Perphenazine can be decreased when combined with Thiabendazole.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Perphenazine.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Perphenazine is combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Perphenazine can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Perphenazine is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Perphenazine.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Perphenazine.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Perphenazine.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Perphenazine is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Perphenazine can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Tilidine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Perphenazine.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Perphenazine.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Perphenazine.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Tolperisone.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Perphenazine.]
[N06AF04, tranylcypromine, The metabolism of Perphenazine can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Trazodone.]
[C03DB02, triamterene, The metabolism of Perphenazine can be decreased when combined with Triamterene.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Triazolam.]
[A03AB12, mepenzolate, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perphenazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Perphenazine is combined with Trifluperidol.]
[N05AA05, triflupromazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Perphenazine.]
[A03AA05, trimebutine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Perphenazine.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Perphenazine.]
[R06AC04, tripelennamine, The metabolism of Perphenazine can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Perphenazine.]
[A03BB01, butylscopolamine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The metabolism of Perphenazine can be decreased when combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Perphenazine.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Tubocurarine.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be decreased when combined with Perphenazine.]
[L02BX03, abiraterone, The serum concentration of Perphenazine can be increased when it is combined with Abiraterone.]
[J05AG05, rilpivirine, The metabolism of Perphenazine can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Ezogabine.]
[C08DA01, verapamil, The metabolism of Perphenazine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Perphenazine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Perphenazine can be decreased when combined with Vinblastine.]
[L01CA02, vincristine, Vincristine may increase the neurotoxic activities of Perphenazine.]
[B01AA03, warfarin, The metabolism of Perphenazine can be decreased when combined with Warfarin.]
[S01AA13, fusidic acid, The metabolism of Perphenazine can be decreased when combined with Fusidic acid.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Perphenazine is combined with Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Levetiracetam.]
[L01EC01, vemurafenib, The serum concentration of Perphenazine can be increased when it is combined with Vemurafenib.]
[J01MA13, trovafloxacin, The metabolism of Perphenazine can be decreased when combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Ziprasidone.]
[G04BD07, tolterodine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, The serum concentration of Atenolol can be increased when it is combined with Perphenazine.]
[L03AB11, peginterferon alfa-2a, The metabolism of Perphenazine can be decreased when combined with Peginterferon alfa-2a.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Perphenazine is combined with Atracurium.]
[S01FA01, atropine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Perphenazine.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Perphenazine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.]
[A08AA11, lorcaserin, The metabolism of Perphenazine can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Perphenazine can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Perphenazine can be decreased when combined with Cobicistat.]
[L04AA31, teriflunomide, The serum concentration of Perphenazine can be decreased when it is combined with Teriflunomide.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Perphenazine is combined with Barbital.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Perphenazine.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.]
[N04BD02, rasagiline, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Perphenazine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Perphenazine is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Perphenazine.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Perphenazine.]
[R06AC06, thonzylamine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Perphenazine can be decreased when combined with Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Perphenazine is combined with Diethyl ether.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Perphenazine.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Perphenazine.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Perphenazine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Perphenazine can be decreased when combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Perphenazine is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Perphenazine can be decreased when combined with Ospemifene.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Perphenazine is combined with Benperidol.]
[J01MA15, gemifloxacin, The metabolism of Perphenazine can be decreased when combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The metabolism of Perphenazine can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Perphenazine can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Perphenazine.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Perphenazine.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Benzocaine.]
[M01AH01, celecoxib, The metabolism of Perphenazine can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Perphenazine.]
[L04AA18, everolimus, The metabolism of Perphenazine can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Benzatropine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Perphenazine is combined with Benzyl alcohol.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Perphenazine.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Perphenazine is combined with Levomilnacipran.]
[C08EA02, bepridil, The metabolism of Bepridil can be decreased when combined with Perphenazine.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Perphenazine.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Vortioxetine is combined with Perphenazine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Perphenazine can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Perphenazine is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Perphenazine.]
[C07AB04, acebutolol, The serum concentration of Acebutolol can be increased when it is combined with Perphenazine.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Perphenazine is combined with Tasimelteon.]
[L04AA32, apremilast, The metabolism of Perphenazine can be increased when combined with Apremilast.]
[S01ED02, betaxolol, The serum concentration of Betaxolol can be increased when it is combined with Perphenazine.]
[L04AC11, siltuximab, The metabolism of Perphenazine can be increased when combined with Siltuximab.]
[A03BA03, hyoscyamine, Perphenazine may increase the anticholinergic activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Perphenazine.]
[L01XH04, belinostat, The metabolism of Perphenazine can be increased when combined with Belinostat.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Alfaxalone.]
[D11AA01, glycopyrronium, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Perphenazine can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Perphenazine can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Acepromazine.]
[A06AH03, naloxegol, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Naloxegol.]
[N04AA02, biperiden, The therapeutic efficacy of Biperiden can be decreased when used in combination with Perphenazine.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Perphenazine.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Perphenazine.]
[N06AX11, mirtazapine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Perphenazine can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Perphenazine can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Perphenazine.]
[A03AA09, difemerine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[J05AP06, asunaprevir, The metabolism of Perphenazine can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Perphenazine is combined with Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Perphenazine can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Perphenazine is combined with Flibanserin.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Cariprazine.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Perphenazine.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Perphenazine.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Perphenazine can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Perphenazine.]
[J02AC05, isavuconazole, The metabolism of Perphenazine can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Perphenazine can be decreased when it is combined with Osimertinib.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Perphenazine.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Perphenazine is combined with Aprobarbital.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Bromazepam.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Perphenazine.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perphenazine.]
[N06AA19, amineptin, The serum concentration of Amineptine can be increased when it is combined with Perphenazine.]
[N05AX17, pimavanserin, Perphenazine may increase the neurotoxic activities of Pimavanserin.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Aniracetam.]
[A05AA04, obeticholic acid, The metabolism of Perphenazine can be decreased when combined with Obeticholic acid.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Perphenazine.]
[C07AA19, bupranolol, The serum concentration of Bupranolol can be increased when it is combined with Perphenazine.]
[N07BC01, buprenorphine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Perphenazine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Artemether is combined with Perphenazine.]
[P01BE03, artesunate, The risk or severity of QTc prolongation can be increased when Artesunate is combined with Perphenazine.]
[N02AF01, butorphanol, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Butorphanol.]
[S01GX07, azelastine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Perphenazine can be decreased when combined with Rucaparib.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Perphenazine.]
[N07XX16, deutetrabenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Perphenazine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Perphenazine is combined with Beclamide.]
[N06BC01, caffeine, The metabolism of Perphenazine can be decreased when combined with Caffeine.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Perphenazine is combined with Oxybuprocaine.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XX08, linezolid, The risk or severity of extrapyramidal symptoms can be increased when Linezolid is combined with Perphenazine.]
[J05AE09, tipranavir, The metabolism of Perphenazine can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Perphenazine.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Perphenazine.]
[L04AB02, infliximab, The metabolism of Perphenazine can be increased when combined with Infliximab.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Perphenazine.]
[N04BD03, safinamide, The therapeutic efficacy of Safinamide can be decreased when used in combination with Perphenazine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Perphenazine.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Perphenazine.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Perphenazine.]
[C07AA17, bopindolol, The serum concentration of Bopindolol can be increased when it is combined with Perphenazine.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Perphenazine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Perphenazine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Brotizolam.]
[N04BX03, budipine, The therapeutic efficacy of Budipine can be decreased when used in combination with Perphenazine.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Perphenazine is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Perphenazine.]
[N06AA15, butriptyline, The serum concentration of Butriptyline can be increased when it is combined with Perphenazine.]
[N01BX04, capsaicin, The metabolism of Perphenazine can be increased when combined with Capsaicin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Perphenazine is combined with Vinylbital.]
[N03AF01, carbamazepine, The metabolism of Perphenazine can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Perphenazine.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Perphenazine.]
[L03AB06, interferon alfa-n1, The metabolism of Perphenazine can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The serum concentration of Carvedilol can be increased when it is combined with Perphenazine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Perphenazine.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Perphenazine.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Perphenazine.]
[C07AB08, celiprolol, The serum concentration of Celiprolol can be increased when it is combined with Perphenazine.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Perphenazine.]
[P01BA07, tafenoquine, The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Perphenazine.]
[N03AX17, stiripentol, The metabolism of Perphenazine can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Perphenazine.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Perphenazine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Perphenazine is combined with Carbromal.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Perphenazine.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Perphenazine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Perphenazine.]
[R03BB08, revefenacin, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Perphenazine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Perphenazine can be decreased when combined with Carmustine.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Perphenazine.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Perphenazine is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Perphenazine.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Esketamine.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Perphenazine is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Brexanolone.]
[N05BA09, clobazam, The metabolism of Perphenazine can be decreased when combined with Clobazam.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Cloxazolam.]
[L04AB01, etanercept, The metabolism of Perphenazine can be increased when combined with Etanercept.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Cyamemazine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Perphenazine.]
[L01EJ02, fedratinib, The metabolism of Perphenazine can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, The metabolism of Perphenazine can be decreased when combined with Pitolisant.]
[N04CX01, istradefylline, The therapeutic efficacy of Istradefylline can be decreased when used in combination with Perphenazine.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Perphenazine.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Perphenazine.]
[A16AX16, givosiran, The serum concentration of Perphenazine can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perphenazine.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Perphenazine.]
[N02AX03, dezocine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Perphenazine is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Perphenazine.]
[M01AX21, diacetylrhein, The metabolism of Perphenazine can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The metabolism of Perphenazine can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Perphenazine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Perphenazine.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Perphenazine.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Perphenazine.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Perphenazine is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Perphenazine.]
[M01AH02, rofecoxib, The metabolism of Perphenazine can be decreased when combined with Rofecoxib.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Perphenazine.]
[C01BD07, dronedarone, The metabolism of Perphenazine can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Perphenazine is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Perphenazine.]
[A03AA08, dihexyverine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The metabolism of Perphenazine can be decreased when combined with Capmatinib.]
[N04BX04, opicapone, The therapeutic efficacy of Opicapone can be decreased when used in combination with Perphenazine.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Perphenazine.]
[P01BE01, artemisinin, The risk or severity of QTc prolongation can be increased when Artemisinin is combined with Perphenazine.]
[G04BD09, trospium, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Perphenazine is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Perphenazine.]
[P01BB01, proguanil, The risk or severity of QTc prolongation can be increased when Proguanil is combined with Perphenazine.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Perphenazine is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Perphenazine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Perphenazine is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Perphenazine can be decreased when combined with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Perphenazine.]
[N05AA01, chlorpromazine, The metabolism of Perphenazine can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Perphenazine.]
[N05AF03, chlorprothixene, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Perphenazine.]
[A11CC05, cholecalciferol, The metabolism of Perphenazine can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Etifoxine.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Perphenazine is combined with Ethyl loflazepate.]
[B06AC06, berotralstat, The metabolism of Perphenazine can be decreased when combined with Berotralstat.]
[L01FX21, naxitamab, Perphenazine may increase the neurotoxic activities of Naxitamab.]
[P03AX07, abametapir, The serum concentration of Perphenazine can be increased when it is combined with Abametapir.]
[V03AF12, trilaciclib, The metabolism of Perphenazine can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Perphenazine is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Perphenazine is combined with Felbamate.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Perphenazine.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Perphenazine.]
[J01MB07, flumequine, The metabolism of Perphenazine can be decreased when combined with Flumequine.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Perphenazine.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Perphenazine.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Perphenazine is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Perphenazine can be increased when it is combined with Peginterferon alfa-2b.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Perphenazine.]
[A02BA01, cimetidine, The metabolism of Perphenazine can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Perphenazine is combined with Gabapentin.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Perphenazine.]
[J01MB06, cinoxacin, The metabolism of Perphenazine can be decreased when combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The metabolism of Perphenazine can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Perphenazine is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Perphenazine can be increased when combined with Somapacitan.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Perphenazine.]
[H01AC09, lonapegsomatropin, The metabolism of Perphenazine can be increased when combined with Lonapegsomatropin.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Perphenazine.]
[M01AG01, mefenamic acid, The metabolism of Perphenazine can be decreased when combined with Mefenamic acid.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Perphenazine.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Perphenazine.]
[J01FF01, clindamycin, Perphenazine may increase the neurotoxic activities of Clindamycin.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Perphenazine is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Perphenazine.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The metabolism of Perphenazine can be decreased when combined with Pacritinib.]
[N06AA04, clomipramine, The serum concentration of desmethylclomipramine, an active metabolite of Clomipramine, can be increased when used in combination with Perphenazine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Perphenazine.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Perphenazine is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Perphenazine is combined with Granisetron.]
[L01XX77, adagrasib, The serum concentration of Perphenazine can be increased when it is combined with Adagrasib.]
[N05AH02, clozapine, The metabolism of Perphenazine can be decreased when combined with Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Perphenazine.]
[H01AC08, somatrogon, The metabolism of Perphenazine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, The risk or severity of extrapyramidal symptoms and CNS depression can be increased when Metyrosine is combined with Perphenazine.]
[L04AC21, bimekizumab, The metabolism of Perphenazine can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Codeine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Perphenazine is combined with Hexafluronium.]
[A03AB10, hexocyclium, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[L04AA13, leflunomide, The serum concentration of Perphenazine can be decreased when it is combined with Leflunomide.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Perphenazine is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Perphenazine is combined with Tropisetron.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Perphenazine.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Perphenazine.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Perphenazine.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Perphenazine.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Desloratadine.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Perphenazine.]
[S01AD03, acyclovir, The metabolism of Perphenazine can be decreased when combined with Acyclovir.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Ketazolam.]
[L01EA01, imatinib, The serum concentration of Perphenazine can be increased when it is combined with Imatinib.]
[N03AX09, lamotrigine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Perphenazine can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The metabolism of Lomefloxacin can be decreased when combined with Perphenazine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Lormetazepam.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA11, manidipine, The metabolism of Perphenazine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Medifoxamine.]
[C07AA14, mepindolol, The serum concentration of Mepindolol can be increased when it is combined with Perphenazine.]
[R06AD07, mequitazine, Perphenazine may increase the arrhythmogenic activities of Mequitazine.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Perphenazine.]
[R03CB02, methoxyphenamine, Perphenazine may decrease the stimulatory activities of Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Perphenazine is combined with Cyclobarbital.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Perphenazine is combined with Melperone.]
[L01AA01, cyclophosphamide, Cyclophosphamide may increase the neurotoxic activities of Perphenazine.]
[N06AX07, minaprine, The risk or severity of extrapyramidal symptoms can be increased when Minaprine is combined with Perphenazine.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Perphenazine.]
[S01XA18, cyclosporine, The metabolism of Perphenazine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of extrapyramidal symptoms can be increased when Moclobemide is combined with Perphenazine.]
[N06BA07, modafinil, The metabolism of Perphenazine can be increased when combined with Armodafinil.]
[R06AX02, cyproheptadine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[J05AF10, entecavir, The metabolism of Perphenazine can be decreased when combined with Entecavir.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Perphenazine.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Perphenazine.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Perphenazine is combined with Dantrolene.]
[J04BA02, dapsone, The risk or severity of QTc prolongation can be increased when Dapsone is combined with Perphenazine.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Perphenazine is combined with Deanol.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Perphenazine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.]
[M01AX01, nabumetone, The metabolism of Perphenazine can be decreased when combined with Nabumetone.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Nordazepam.]
[C07AB12, nebivolol, The serum concentration of Nebivolol can be increased when it is combined with Perphenazine.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Niaprazine.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Tiagabine.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Perphenazine.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Perphenazine.]
[R05DA06, normethadone, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Normethadone.]
[N06AB10, escitalopram, The serum concentration of Perphenazine can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, The metabolism of Perphenazine can be decreased when combined with Desipramine.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Perphenazine.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Oxiracetam.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Perphenazine.]
[G04BD04, oxybutynin, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Perphenazine.]
[A03AA01, oxyphencyclimine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Perphenazine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Perphenazine.]
[N06BA02, dextroamphetamine, Perphenazine may decrease the stimulatory activities of Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Perphenazine.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Perphenazine.]
[N02AC01, dextromoramide, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Dextromoramide.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Perphenazine.]
[N06AB05, paroxetine, The metabolism of Perphenazine can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Perphenazine can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Diamorphine.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Perphenazine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Perphenazine.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Perphenazine is combined with Phenacemide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Perphenazine.]
[N06AA08, dibenzepin, The serum concentration of Dibenzepin can be increased when it is combined with Perphenazine.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Perphenazine.]
[S01BC03, diclofenac, The metabolism of Perphenazine can be decreased when combined with Diclofenac.]
[A03AA07, dicyclomine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Perphenazine may increase the neurotoxic activities of Didanosine.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Pipamperone.]
[A03AB14, pipenzolate, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Perphenazine.]
[A08AA03, diethylpropion, Perphenazine may decrease the stimulatory activities of Diethylpropion.]
[A03AB11, poldine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C02DB01, dihydralazine, The metabolism of Perphenazine can be decreased when combined with Dihydralazine.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Perphenazine.]
[N02AA03, hydromorphone, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Hydromorphone.]
[J05AE08, atazanavir, The metabolism of Perphenazine can be decreased when combined with Atazanavir.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Perphenazine.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Perphenazine.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Perphenazine is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Perphenazine is combined with Pridinol.]
[R06AB03, dimethindene, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, The metabolism of Perphenazine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The therapeutic efficacy of Progabide can be decreased when used in combination with Perphenazine.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Perphenazine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Perphenazine.]
[R06AA02, diphenhydramine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Perphenazine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The serum concentration of Quinupramine can be increased when it is combined with Perphenazine.]
[A03FA02, cisapride, The metabolism of Perphenazine can be decreased when combined with Cisapride.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Perphenazine.]
[C01BA03, disopyramide, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Perphenazine can be decreased when combined with Rifamycin.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Perphenazine.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Perphenazine.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Perphenazine.]
[J01MB01, rosoxacin, The metabolism of Perphenazine can be decreased when combined with Rosoxacin.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Perphenazine.]
[C01EB18, ranolazine, The serum concentration of Perphenazine can be increased when it is combined with Ranolazine.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Perphenazine.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Perphenazine.]
[N06AA16, dothiepin, The metabolism of Perphenazine can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The serum concentration of Doxepin can be increased when it is combined with Perphenazine.]
[L01DB01, doxorubicin, The metabolism of Perphenazine can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Perphenazine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Perphenazine is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Perphenazine.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Perphenazine is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Perphenazine.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Perphenazine.]
[J01MA05, temafloxacin, The metabolism of Perphenazine can be decreased when combined with Temafloxacin.]
[D01BA02, terbinafine, The metabolism of Perphenazine can be decreased when combined with Terbinafine.]
[C07AA16, tertatolol, The serum concentration of Tertatolol can be increased when it is combined with Perphenazine.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Perphenazine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Perphenazine is combined with Thiopropazate.]
[G04BD01, emepronium, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The serum concentration of Tianeptine can be increased when it is combined with Perphenazine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Tofisopam.]
[N06AG03, toloxatone, The risk or severity of extrapyramidal symptoms can be increased when Toloxatone is combined with Perphenazine.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Perphenazine.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Perphenazine.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Perphenazine is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Perphenazine is combined with Triclofos.]
[A03AB08, tridihexethyl, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Perphenazine.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Perphenazine.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Perphenazine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Perphenazine.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Perphenazine is combined with Urapidil.]
[J01MA04, enoxacin, The metabolism of Perphenazine can be decreased when combined with Enoxacin.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Perphenazine is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Perphenazine can be decreased when combined with Vinorelbine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Perphenazine.]
[N06AX16, venlafaxine, The metabolism of Perphenazine can be decreased when combined with Venlafaxine.]
[N05CF02, zolpidem, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Perphenazine is combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Perphenazine.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Perphenazine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Perphenazine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perphenazine.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Ergotamine is combined with Perphenazine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Perphenazine.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Estazolam.]
[H05BX01, cinacalcet, The metabolism of Perphenazine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Perphenazine can be decreased when combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Perphenazine can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Perphenazine can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Perphenazine.]
[C01CA15, gepefrine, Perphenazine may decrease the stimulatory activities of Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perphenazine.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Perphenazine.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Perphenazine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Perphenazine.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Perphenazine.]
[S01XA06, ethylmorphine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Ethylmorphine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Perphenazine.]
[L01CB01, etoposide, The metabolism of Perphenazine can be decreased when combined with Etoposide.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Perphenazine is combined with Sertindole.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Perphenazine.]
[R06AX12, terfenadine, The metabolism of Perphenazine can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Perphenazine can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Perphenazine can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Perphenazine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Perphenazine.]
[A02BA03, famotidine, The metabolism of Perphenazine can be decreased when combined with Famotidine.]
[P02CA03, albendazole, The metabolism of Perphenazine can be increased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Perphenazine can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Perphenazine.]
[N02AB03, fentanyl, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Fentanyl.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Perphenazine.]
[G04BD02, flavoxate, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Perphenazine.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Flunitrazepam.]
[N06AA14, melitracen, The serum concentration of Melitracen can be increased when it is combined with Perphenazine.]
[V03AZ01, ethanol, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC02, fluorouracil, The metabolism of Perphenazine can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, The serum concentration of Perphenazine can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Perphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Perphenazine.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Perphenazine is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Perphenazine can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Perphenazine.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Perphenazine is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of extrapyramidal symptoms can be increased when Furazolidone is combined with Perphenazine.]
[J05AE10, darunavir, The serum concentration of Perphenazine can be increased when it is combined with Darunavir.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Perphenazine is combined with Eszopiclone.]
[N05AL05, amisulpride, Perphenazine may increase the antipsychotic activities of Amisulpride.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Perphenazine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Gallamine.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Perphenazine is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Perphenazine can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Perphenazine.]
[N04BC06, cabergoline, The therapeutic efficacy of Cabergoline can be decreased when used in combination with Perphenazine.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Perphenazine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Perphenazine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Alfentanil.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Perphenazine.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Perphenazine.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Perphenazine.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perphenazine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Perphenazine is combined with Glutethimide.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Perphenazine.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Perphenazine.]
[L01EX02, sorafenib, The metabolism of Perphenazine can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, The serum concentration of Esmolol can be increased when it is combined with Perphenazine.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Perphenazine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Perphenazine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Perphenazine is combined with Halothane.]
[N05AH04, quetiapine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Perphenazine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Perphenazine is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Perphenazine is combined with Allobarbital.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Perphenazine is combined with Hexobarbital.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Perphenazine.]
[R05DA03, hydrocodone, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[G04BD06, propiverine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Perphenazine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Perphenazine is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.]
[B05CB02, sodium citrate, Perphenazine may increase the neurotoxic activities of Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Perphenazine.]
[H01AC02, somatrem, The metabolism of Perphenazine can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Sufentanil.]
[N06AA02, imipramine, The metabolism of Perphenazine can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, Perphenazine may increase the neurotoxic activities of Paclitaxel.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Perphenazine.]
[L03AB04, interferon alfa-2a, The metabolism of Perphenazine can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Perphenazine can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Perphenazine is combined with Milnacipran.]
[A03AA30, piperidolate, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Articaine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Perphenazine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Perphenazine is combined with Ramelteon.]
[R06AE01, buclizine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Perphenazine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The metabolism of Perphenazine can be decreased when combined with Anagrelide.]
[C07AA01, alprenolol, The serum concentration of Alprenolol can be increased when it is combined with Perphenazine.]
[L03AB09, interferon alfacon-1, The metabolism of Perphenazine can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Perphenazine.]
[J05AF04, stavudine, Stavudine may increase the neurotoxic activities of Perphenazine.]
[N06AA13, iprindole, The serum concentration of Iprindole can be increased when it is combined with Perphenazine.]
[N06AF05, iproniazid, The risk or severity of extrapyramidal symptoms can be increased when Iproniazid is combined with Perphenazine.]
[J05AB13, penciclovir, The metabolism of Perphenazine can be decreased when combined with Penciclovir.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of extrapyramidal symptoms can be increased when Isocarboxazid is combined with Perphenazine.]
[P01AX06, atovaquone, The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Perphenazine.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Perphenazine.]
[N04BX02, entacapone, The therapeutic efficacy of Entacapone can be decreased when used in combination with Perphenazine.]
[J04AC01, isoniazid, The metabolism of Perphenazine can be decreased when combined with Isoniazid.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Perphenazine.]
[H01AC01, somatropin, The metabolism of Perphenazine can be increased when combined with Somatotropin.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC07, tocilizumab, The metabolism of Perphenazine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Perphenazine is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Perphenazine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[V03AC03, deferasirox, The serum concentration of Perphenazine can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Perphenazine can be increased when combined with Abatacept.]
[N04BC09, rotigotine, Perphenazine may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The metabolism of Perphenazine can be decreased when combined with Nalidixic acid.]
[C07AG01, labetalol, The serum concentration of Labetalol can be increased when it is combined with Perphenazine.]
[N04BB01, amantadine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Perphenazine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Perphenazine is combined with Lacosamide.]
[N04BA01, levodopa, The therapeutic efficacy of Levodopa can be decreased when used in combination with Perphenazine.]
[S02DA01, lidocaine, The metabolism of Perphenazine can be decreased when combined with Lidocaine.]
[J01FF02, lincomycin, Perphenazine may increase the neurotoxic activities of Lincomycin.]
[N06BA13, armodafinil, The metabolism of Perphenazine can be increased when combined with Armodafinil.]
[N02CA07, lisuride, The therapeutic efficacy of Lisuride can be decreased when used in combination with Perphenazine.]
[N06AA07, lofepramine, The serum concentration of Lofepramine can be increased when it is combined with Perphenazine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Perphenazine.]
[C10AA02, lovastatin, The metabolism of Perphenazine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Perphenazine.]
[L01EG01, temsirolimus, The metabolism of Perphenazine can be decreased when combined with Temsirolimus.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Perphenazine can be increased when used in combination with Magnesium sulfate.]
[N06AA21, maprotiline, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Perphenazine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Perphenazine.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Medazepam.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Perphenazine.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Perphenazine is combined with Melatonin.]
[N06DX01, memantine, The therapeutic efficacy of Memantine can be decreased when used in combination with Perphenazine.]
[N02AB02, meperidine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Meperidine.]
[C01CA11, mephentermine, Perphenazine may decrease the stimulatory activities of Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Perphenazine.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Perphenazine.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Perphenazine.]
[N02AX05, meptazinol, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Perphenazine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Perphenazine.]
[N06BA03, methamphetamine, Perphenazine may decrease the stimulatory activities of Metamfetamine.]
[A03AB07, methantheline, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Perphenazine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Perphenazine.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Perphenazine is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Perphenazine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The metabolism of Perphenazine can be decreased when combined with Pemetrexed.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Perphenazine.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Perphenazine.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Perphenazine is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Perphenazine can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Perphenazine is combined with Methoxyflurane.]
[V04CG05, methylene blue, The risk or severity of extrapyramidal symptoms can be increased when Methylene blue is combined with Perphenazine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Perphenazine.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Perphenazine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Perphenazine is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Perphenazine.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Perphenazine.]
[C07AB02, metoprolol, The metabolism of Perphenazine can be decreased when combined with Metoprolol.]
[C01BB02, mexiletine, The metabolism of Perphenazine can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Mianserin is combined with Perphenazine.]
[S02AA13, miconazole, The metabolism of Perphenazine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Perphenazine.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Perphenazine.]
[G03XB01, mifepristone, The metabolism of Perphenazine can be decreased when combined with Mifepristone.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.]
[N06BA12, lisdexamfetamine, Perphenazine may decrease the stimulatory activities of Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Molindone.]
[C01BD01, amiodarone, The metabolism of Perphenazine can be decreased when combined with Amiodarone.]
[N02AA01, morphine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Morphine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Perphenazine.]
[L04AB05, certolizumab pegol, The metabolism of Perphenazine can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Perphenazine.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Perphenazine.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Perphenazine is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Perphenazine is combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Perphenazine.]
[R03BB01, ipratropium bromide, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, The serum concentration of Amoxapine can be increased when it is combined with Perphenazine.]
[N03AB05, fosphenytoin, The serum concentration of Fosphenytoin can be increased when it is combined with Perphenazine.]
[L03AB08, interferon beta-1b, The metabolism of Perphenazine can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, The serum concentration of Nadolol can be increased when it is combined with Perphenazine.]
[N04BC04, ropinirole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Perphenazine.]
[J01CF06, nafcillin, The metabolism of Perphenazine can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Perphenazine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Nalbuphine.]
[N07BB04, naltrexone, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Naltrexone.]
[L04AC03, anakinra, The metabolism of Perphenazine can be increased when combined with Anakinra.]
[N06BA01, amphetamine, Perphenazine may decrease the stimulatory activities of Amphetamine.]
[M02AA12, naproxen, The metabolism of Perphenazine can be decreased when combined with Naproxen.]
[N06AX21, duloxetine, The metabolism of Perphenazine can be decreased when combined with Duloxetine.]
[N04BX01, tolcapone, The therapeutic efficacy of Tolcapone can be decreased when used in combination with Perphenazine.]
[S03AA01, neomycin, Perphenazine may increase the neurotoxic activities of Neomycin.]
[N01AH06, remifentanil, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Remifentanil.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Perphenazine is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Desvenlafaxine.]
[C10AD02, niacin, The metabolism of Perphenazine can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of extrapyramidal symptoms can be increased when Nialamide is combined with Perphenazine.]
[C08CA04, nicardipine, The metabolism of Perphenazine can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Perphenazine.]
[P02DA01, niclosamide, The metabolism of Perphenazine can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Perphenazine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Nitrazepam.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Perphenazine is combined with Zaleplon.]
[N04BC05, pramipexole, The therapeutic efficacy of Pramipexole can be decreased when used in combination with Perphenazine.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Perphenazine is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Nomifensine.]
[S01AE02, norfloxacin, The metabolism of Perphenazine can be decreased when combined with Norfloxacin.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Perphenazine.]
[L03AB07, interferon beta-1a, The metabolism of Perphenazine can be decreased when combined with Interferon beta-1a.]
[L04AC04, rilonacept, The metabolism of Perphenazine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Perphenazine can be increased when combined with Omeprazole.]
[N06AA05, opipramol, The serum concentration of Opipramol can be increased when it is combined with Perphenazine.]
[N02AA02, opium, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Opium.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Perphenazine.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Perphenazine.]
[P02BA02, oxamniquine, The metabolism of Perphenazine can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Perphenazine.]
[C07AA02, oxprenolol, The serum concentration of Oxprenolol can be increased when it is combined with Perphenazine.]
[N02AA05, oxycodone, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Oxycodone.]
[N02AA11, oxymorphone, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Oxypertine.]
[A03AB03, oxyphenonium, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.]
[M03AC01, pancuronium, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[N05CC05, paraldehyde, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of extrapyramidal symptoms can be increased when Pargyline is combined with Perphenazine.]
[J01MA03, pefloxacin, The metabolism of Perphenazine can be decreased when combined with Pefloxacin.]
[G04BD11, fesoterodine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The serum concentration of Penbutolol can be increased when it is combined with Perphenazine.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Perphenazine is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Perphenazine.]
[C04AD03, pentoxifylline, The metabolism of Perphenazine can be decreased when combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Perazine.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Perphenazine.]
[C08EX02, perhexiline, The metabolism of Perphenazine can be decreased when combined with Perhexiline.]
[J01MB04, pipemidic acid, The metabolism of Perphenazine can be decreased when combined with Pipemidic acid.]
[N07XX04, sodium oxybate, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Perphenazine.]
[N02AD02, phenazocine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of extrapyramidal symptoms can be increased when Phenelzine is combined with Perphenazine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Perphenazine.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Perphenazine is combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Phenoperidine.]
[A08AA01, phentermine, Perphenazine may decrease the stimulatory activities of Phentermine.]
[S01GA05, phenylephrine, The metabolism of Perphenazine can be increased when combined with Phenylephrine.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be increased when it is combined with Perphenazine.]
[L04AB06, golimumab, The metabolism of Perphenazine can be increased when combined with Golimumab.]
[C08CX01, mibefradil, The metabolism of Perphenazine can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Perphenazine.]
[C07AA03, pindolol, The serum concentration of Pindolol can be increased when it is combined with Perphenazine.]
[J05AE01, saquinavir, The metabolism of Perphenazine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Perphenazine.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Pipotiazine.]
[A02BX03, pirenzepine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The therapeutic efficacy of Piribedil can be decreased when used in combination with Perphenazine.]
[N02AC03, pirinitramide, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Piritramide.]
[J01MA11, grepafloxacin, The metabolism of Perphenazine can be decreased when combined with Grepafloxacin.]
[N02CX01, pizotyline, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Perphenazine can be decreased when combined with Delavirdine.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Perphenazine is combined with Proxibarbal.]
[A03AE01, alosetron, The metabolism of Perphenazine can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Perphenazine can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, Perphenazine may increase the neurotoxic activities of Polymyxin B.]
[J05AE03, ritonavir, The metabolism of Perphenazine can be decreased when combined with Ritonavir.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Perphenazine.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Perphenazine.]
[C07AB01, practolol, The serum concentration of Practolol can be increased when it is combined with Perphenazine.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Perphenazine is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Perphenazine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Perphenazine.]
[P01BA03, primaquine, The metabolism of Perphenazine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Perphenazine can be increased when combined with Primidone.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Perphenazine.]
[S01HA05, procaine, The risk or severity of extrapyramidal symptoms can be increased when Procaine is combined with Perphenazine.]
[L01XB01, procarbazine, The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Perphenazine.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perphenazine.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Perphenazine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Perphenazine.]
[N05AA03, promazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The metabolism of Perphenazine can be decreased when combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Perphenazine is combined with Propanidid.]
[A03AB05, propantheline, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Periciazine.]
[N05CM06, propiomazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Perphenazine.]
[N02AC04, propoxyphene, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Perphenazine.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Perphenazine.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Perphenazine.]
[N06AA11, protriptyline, The serum concentration of Protriptyline can be increased when it is combined with Perphenazine.]
[R01BA02, pseudoephedrine, Perphenazine may decrease the stimulatory activities of Pseudoephedrine.]
[N05AX12, aripiprazole, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Perphenazine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Perphenazine is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Perphenazine is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Perphenazine is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Mepyramine.]
[P01BD01, pyrimethamine, The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Perphenazine.]
[P01AX05, quinacrine, The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Perphenazine.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Quinidine is combined with Perphenazine.]
[P01BC01, quinine, The metabolism of Perphenazine can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Perphenazine can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Perphenazine.]
[J04AB02, rifampin, The metabolism of Perphenazine can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Perphenazine is combined with Oxitriptan.]
[S01FA02, scopolamine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Perphenazine.]
[N04BD01, selegiline, The therapeutic efficacy of Selegiline can be decreased when used in combination with Perphenazine.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Perphenazine.]
